Abstract:The 3C-like proteinase (3CLpro) of severe acute respiratory syndrome (SARS) coronavirus has been proposed to be a key target for anti-SARS drug discovery. It has been proposed and verified that the dimer was the active form of 3CLpro and only one protomer is active In our previous work, we measured the dissociation constant (K-d) of the purified SARS 3CLpro using analytical ultracentrifugation at around 14.0 mu mol . L-1 Using this K-d value, most of the SARS 3CLpro in the in vitro activity assay (1-3 mu m . L-1) might be in the monomer form and inactive. To explain this dilemma, we measured the enzyme activity change together with the enzyme concentration. By fitting the concentration dependent activity profile, the apparent dissociation constant was found to be 094 mu mol . L-1. Indicating a clear tendency toward substrate enhanced dimerization. This also explains why SARS 3CLpro was still active in the in vitro activity assay under a relatively low enzyme concentration. To further verify the substrate induced dimerization phenomenon, we selected a previously reported SARS 3CLpro isatin inhibitor, 1-(2-naphthlmethyl) isatin-5-carboxamide (5f), which has similar binding interactions with the substrate and we studied its influence on SARS 3CLpro dimer formation using analytical ultracentrifugation 5f showed a strong ability to Induce SARS 3CLpro dimer formation By measuring the dimer and monomer distribution under different 5f concentrations, the EC50 of dirtier induction was found to be about 1.0 mu mol . L-1 under an enzyme concentration of 3 0 mu mol . L-1. This implies that only one protomer in the SARS 3CLpro choler binds to the inhibitor or the substrate. As the apparent association constant and thus the enzyme activity of SARS 3CLpro increases with the concentration of the substrate, this may be a smart way to allostetrically regulate the hydrolysis of the SARS viral polyproteins and the correct assembly of virons

Substrate Binding and Homo-Dimerization of SARS 3CL Proteinase Are Mutual Allosteric Effectors

Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-Like Proteinase

Only One Protomer is Active in the Dimer of Sars 3C-Like Proteinase

Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.

3C-Like Proteinase from SARS Coronavirus Catalyzes Substrate Hydrolysis by a General Base Mechanism

The interaction between severe acute respiratory syndrome coronavirus 3C-like proteinase and a dimeric inhibitor by capillary electrophoresis.

Maturation Mechanism of Severe Acute Respiratory Syndrome (SARS) Coronavirus 3C-Like Proteinase.

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

The N-Terminal Octapeptide Acts As A Dimerization Inhibitor of Sars Coronavirus 3C-Like Proteinase

The Substrate Specificity of SARS Coronavirus 3C-Like Proteinase.

Insight into the activity of SARS main protease: Molecular dynamics study of dimeric and monomeric form of enzyme.

Isatin Dual Functional Inhibitors: Modulating the Aggregation State and Enzyme Activity of SARS-3CL Proteinase

[Modeling of the SARS Coronavirus Main Proteinase and Conformational Flexibility of the Active Site].

Conformational Flexibility of a Short Loop Near the Active Site of the SARS-3CLpro is Essential to Maintain Catalytic Activity

Rapid Peptide-Based Screening on the Substrate Specificity of Severe Acute Respiratory Syndrome (SARS) Coronavirus 3C-Like Protease by Matrix-Assisted Laser Desorption/ionization Time-of-flight Mass Spectrometry.

Without Its N-Finger, the Main Protease of Severe Acute Respiratory Syndrome Coronavirus Can Form a Novel Dimer Through Its C-Terminal Domain

Comprehensive Insights into the Catalytic Mechanism of Middle East Respiratory Syndrome 3C-Like Protease and Severe Acute Respiratory Syndrome 3C-Like Protease

The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors

Characterization of alternate encounter assemblies of SARS-CoV-2 main protease

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Three-dimensional domain swapping as a mechanism to lock the active conformation in a super-active octamer of SARS-CoV main protease